GleamWall
中文EN

QTTB Q32 Bio Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661998 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY176.6%
TTM EPS YoY210.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE24.0%
ROA18.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.2%
Debt / equity0.00x
Current ratio56.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.62x
Accruals ratio29.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$53.74M$0
R&D expense$19.16M$48.14M
SG&A expense$17.68M$17.96M
Operating income$16.90M-$66.10M
Pretax income$29.82M-$46.09M
Income tax$0$21,000
Net income$29.82M-$47.73M
EBITDA$17.29M-$65.61M
EPS (basic)2.42-5.12
EPS (diluted)2.42-6.58
Weighted avg. shares (diluted)12.31M9.66M
Banking
Net interest income$1.05M$2.83M
Balance sheet
Cash & equivalents$48.30M$78.61M
Short-term investments—$0
Current assets$55.05M$81.88M
PP&E, net$979,000$1.37M
Total assets$61.78M$92.33M
Current liabilities$11.35M$16.46M
Total liabilities$19.76M$86.66M
Shareholders' equity$42.01M$5.67M
Shares outstanding12.86M12.20M
Cash flow statement
Operating cash flow-$33.54M-$67.72M
Capital expenditure$0$75,000
Free cash flow-$33.54M-$67.79M
Investing cash flow$7.00M$19.93M
Financing cash flow-$3.12M$95.14M
Depreciation & amortization$391,000$487,000
Stock-based compensation$5.25M$4.39M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.